Outcome of Board Meeting Held on 20th May, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals' board, at its 20 May 2025 meeting, approved the audited standalone financial results for Q4 and FY ended 31 March 2025. Revenue from operations rose about 7% to Rs. 15,169.15 lakhs (vs Rs. 14,196.65 lakhs), while profit after tax grew around 23% to Rs. 3,206.06 lakhs (vs Rs. 2,597.73 lakhs), pushing EPS to Rs. 72.65 from Rs. 58.86. The board recommended a dividend of Rs. 21.80 per share (180%) on 44,13,300 equity shares for FY25. The 40th AGM is scheduled for 18 July 2025 via video conferencing. Shri Ashish Uttam Bhuta was re-appointed as Chairman & Managing Director for five years from 1 April 2026 to 31 March 2031. Auditor D.R. Mehta & Associates issued an unmodified (clean) opinion on the financial statements, and operating cash flow more than tripled to Rs. 2,790.60 lakhs.
A clean audit, healthy ~23% PAT growth, a generous 180% dividend, and a debt-light balance sheet (reserves of Rs. 16,736 lakhs vs borrowings under Rs. 200 lakhs) signal financial strength and shareholder-friendly returns, likely to be viewed positively by investors.